Lessons from Recent Advances in Ischemic Stroke Management and Targeting Kv2.1 for Neuroprotection
Achieving neuroprotection in ischemic stroke patients has been a multidecade medical challenge. Numerous clinical trials were discontinued in futility and many were terminated in response to deleterious treatment effects. Recently, however, several positive reports have generated the much-needed exc...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-08-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/21/17/6107 |
| _version_ | 1797555740989194240 |
|---|---|
| author | Chung-Yang Yeh Anthony J. Schulien Bradley J. Molyneaux Elias Aizenman |
| author_facet | Chung-Yang Yeh Anthony J. Schulien Bradley J. Molyneaux Elias Aizenman |
| author_sort | Chung-Yang Yeh |
| collection | DOAJ |
| description | Achieving neuroprotection in ischemic stroke patients has been a multidecade medical challenge. Numerous clinical trials were discontinued in futility and many were terminated in response to deleterious treatment effects. Recently, however, several positive reports have generated the much-needed excitement surrounding stroke therapy. In this review, we describe the clinical studies that significantly expanded the time window of eligibility for patients to receive mechanical endovascular thrombectomy. We further summarize the results available thus far for nerinetide, a promising neuroprotective agent for stroke treatment. Lastly, we reflect upon aspects of these impactful trials in our own studies targeting the Kv2.1-mediated cell death pathway in neurons for neuroprotection. We argue that recent changes in the clinical landscape should be adapted by preclinical research in order to continue progressing toward the development of efficacious neuroprotective therapies for ischemic stroke. |
| first_indexed | 2024-03-10T16:51:47Z |
| format | Article |
| id | doaj.art-66933aa3a3c647ddab673cf6fa6ebd0d |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-10T16:51:47Z |
| publishDate | 2020-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-66933aa3a3c647ddab673cf6fa6ebd0d2023-11-20T11:15:45ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672020-08-012117610710.3390/ijms21176107Lessons from Recent Advances in Ischemic Stroke Management and Targeting Kv2.1 for NeuroprotectionChung-Yang Yeh0Anthony J. Schulien1Bradley J. Molyneaux2Elias Aizenman3Department of Neurobiology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USADepartment of Neurobiology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USAPittsburgh Institute for Neurodegenerative Diseases, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USADepartment of Neurobiology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USAAchieving neuroprotection in ischemic stroke patients has been a multidecade medical challenge. Numerous clinical trials were discontinued in futility and many were terminated in response to deleterious treatment effects. Recently, however, several positive reports have generated the much-needed excitement surrounding stroke therapy. In this review, we describe the clinical studies that significantly expanded the time window of eligibility for patients to receive mechanical endovascular thrombectomy. We further summarize the results available thus far for nerinetide, a promising neuroprotective agent for stroke treatment. Lastly, we reflect upon aspects of these impactful trials in our own studies targeting the Kv2.1-mediated cell death pathway in neurons for neuroprotection. We argue that recent changes in the clinical landscape should be adapted by preclinical research in order to continue progressing toward the development of efficacious neuroprotective therapies for ischemic stroke.https://www.mdpi.com/1422-0067/21/17/6107ischemic strokereperfusionneuroprotectionnerinetideKv2.1 |
| spellingShingle | Chung-Yang Yeh Anthony J. Schulien Bradley J. Molyneaux Elias Aizenman Lessons from Recent Advances in Ischemic Stroke Management and Targeting Kv2.1 for Neuroprotection International Journal of Molecular Sciences ischemic stroke reperfusion neuroprotection nerinetide Kv2.1 |
| title | Lessons from Recent Advances in Ischemic Stroke Management and Targeting Kv2.1 for Neuroprotection |
| title_full | Lessons from Recent Advances in Ischemic Stroke Management and Targeting Kv2.1 for Neuroprotection |
| title_fullStr | Lessons from Recent Advances in Ischemic Stroke Management and Targeting Kv2.1 for Neuroprotection |
| title_full_unstemmed | Lessons from Recent Advances in Ischemic Stroke Management and Targeting Kv2.1 for Neuroprotection |
| title_short | Lessons from Recent Advances in Ischemic Stroke Management and Targeting Kv2.1 for Neuroprotection |
| title_sort | lessons from recent advances in ischemic stroke management and targeting kv2 1 for neuroprotection |
| topic | ischemic stroke reperfusion neuroprotection nerinetide Kv2.1 |
| url | https://www.mdpi.com/1422-0067/21/17/6107 |
| work_keys_str_mv | AT chungyangyeh lessonsfromrecentadvancesinischemicstrokemanagementandtargetingkv21forneuroprotection AT anthonyjschulien lessonsfromrecentadvancesinischemicstrokemanagementandtargetingkv21forneuroprotection AT bradleyjmolyneaux lessonsfromrecentadvancesinischemicstrokemanagementandtargetingkv21forneuroprotection AT eliasaizenman lessonsfromrecentadvancesinischemicstrokemanagementandtargetingkv21forneuroprotection |